Novo Nordisk ($NVO) filed a lawsuit against Eli Lilly ($LLY), alleging Lilly’s advertising for Zepbound and Mounjaro relies on outdated clinical comparisons that understate the performance of Novo’s latest higher-dose Wegovy and Ozempic treatments. Novo is seeking to halt the advertising, require corrective marketing, and recover damages as the companies compete in the growing obesity drug market
- Novo alleges Lilly’s Zepbound ads compare against an older, lower-dose version of Wegovy used in the SURMOUNT-5 study rather than the FDA-approved higher-dose formulation launched in April.
- The lawsuit also challenges Lilly’s Mounjaro advertising, claiming comparisons to Ozempic rely on outdated dosing data.
- Novo is seeking an injunction, corrective advertising, and recovery of lost profits under federal and state false advertising laws.
- The companies are competing for share in the global obesity treatment market, which Bloomberg Intelligence projects could reach $120 billion annually by 2030.
- Novo Nordisk ($NVO) – The company is pursuing legal action to challenge competing obesity and diabetes drug advertising and protect market share.
- Eli Lilly ($LLY) – Faces false advertising and unfair competition claims related to marketing for Zepbound and Mounjaro.
Editor’s Note: This is a developing story. This article may be updated as more details become available
